Praxis Precision Medicines, Inc. (PRAX) vs Spyre Therapeutics, Inc. (SYRE)

Praxis Precision Medicines, Inc. and Spyre Therapeutics, Inc. are both Biotechnology companies. Praxis Precision Medicines, Inc. and Spyre Therapeutics, Inc. are of similar size ($7.9B and $7.7B). Praxis Precision Medicines, Inc. grew revenue faster over the last twelve months: 249.5% against −81.8%. Across the 12 metrics below, Spyre Therapeutics, Inc. leads on 7 and Praxis Precision Medicines, Inc. on 5.

Valuation

Metric PRAX SYRE Biotechnology median
P/E n/m n/m 7.88
P/S 956.32 6,931.86 11.47
P/B 6.10 7.65 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 867.63 5,845.20 10.73
Earnings yield (4.61%) (2.48%) (28.84%)
Free cash flow yield (3.74%) (2.85%) (23.03%)

Profitability

Metric PRAX SYRE Biotechnology median
Gross margin 100.00% 100.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (38.86%) (28.52%) (57.72%)
Return on assets (36.80%) (20.90%) (49.22%)
Return on invested capital (40.58%) 0.00% 0.00%

Growth

Metric PRAX SYRE Biotechnology median
Revenue growth (TTM) 249.53% (81.84%) 5.64%
EPS growth (last fiscal year) (32.03%) 55.24% —
Revenue growth, 5-year CAGR — (28.15%) 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric PRAX SYRE Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 15.73 18.53 4.73
Net debt to EBITDA 1.82 3.61 0.96

Dividend

Metric PRAX SYRE Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric PRAX SYRE Biotechnology median
Market cap 7.87b 7.68b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack